Division of Ethnopharmacology, Entomology Research Institute, Loyola College, Chennai-600034, Tamil Nadu, India.
Xavier Research Foundation, St Xavier's College, Palayamkottai - 627002, Tamil Nadu, India.
Curr Pharm Des. 2020;26(22):2602-2609. doi: 10.2174/1381612826666200211122633.
Systemic lupus erythematosus (SLE) is an autoimmune disease in mankind. SLE's downregulation of T and B lymphocytes could cause the development of autoantibodies, which in turn attack cell surface, nuclear, and cytoplasmic molecules, creating immune complexes that harm tissues.
The objective of the present review is to evaluate SLE's present therapeutic policies and raise consciousness about the disease.
New therapies are rare for SLE. This is due to the complexity of the disease and its various manifestations. Three techniques are used to develop biological treatments for the illness: B-cell modulation, T-cell regulation and cytokine inhibition. This paper reviews the present trends in SLE therapy.
Each arm of the immune system is a prospective therapeutic development target for this disease; it involves B-cells, T-cells, interferon (IFN) and cytokines. To date, only one of these agents is been approved for use against lupus, belimumab which comes under B-cell therapy. Both the innate and the adaptive immune systems are the objectives. Currently, although there is no full SLE remedy, drug therapy can minimize organ injury and control active disease, which relies on immunosuppressants and glucocorticoids.
It is possible to access SLE treatment in the form of T-cell, B-cell and anticytokine therapies. In these therapies, antibodies and antigens interactions play a major part. Another medication for treating SLE is the non-steroidal anti-inflammatory drug such as hydroxychloroquine. Glucocorticoids (GCs) are another antiinflammatory treatment that suppresses the growth of cytokines related to inflammation and prevents the recruitment of leukocyte by reducing endothelial cell permeability.
系统性红斑狼疮（SLE）是一种人类自身免疫性疾病。SLE 下调 T 和 B 淋巴细胞会导致自身抗体的产生，进而攻击细胞表面、核和细胞质分子，产生免疫复合物，损害组织。
本综述旨在评估 SLE 的现有治疗策略并提高对该疾病的认识。
SLE 很少有新的治疗方法。这是由于疾病的复杂性及其各种表现。目前有三种技术用于开发针对该疾病的生物治疗方法：B 细胞调节、T 细胞调节和细胞因子抑制。本文回顾了 SLE 治疗的现状。
免疫系统的每一个分支都是这种疾病的潜在治疗靶点，包括 B 细胞、T 细胞、干扰素（IFN）和细胞因子。迄今为止，只有一种此类药物被批准用于狼疮治疗，即属于 B 细胞治疗的贝利尤单抗。固有免疫和适应性免疫系统都是目标。目前，尽管没有针对 SLE 的完全治愈方法，但药物治疗可以最大程度地减少器官损伤并控制活动性疾病，这依赖于免疫抑制剂和糖皮质激素。
可以通过 T 细胞、B 细胞和抗细胞因子治疗来获得 SLE 的治疗方法。在这些治疗中，抗体和抗原的相互作用起着主要作用。另一种治疗 SLE 的药物是非甾体类抗炎药，如羟氯喹。糖皮质激素（GCs）是另一种抗炎治疗方法，通过抑制与炎症相关的细胞因子的生长并通过降低内皮细胞通透性来阻止白细胞的募集，从而发挥作用。
